BI 3000202
Alternative Names: BI-3000202Latest Information Update: 22 May 2024
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 17 May 2024 Boehringer Ingelheim plans a phase I pharmacokinetics trial in Healthy adult volunteers (PO) in May 2024 (NCT06419660) (EudraCT2023-509209-54-00)
- 13 Nov 2023 Boehringer Ingelheim completes a phase I safety and pharmacokinetics trial Healthy adult volunteers in Germany (PO) (NCT05945888) (EudraCT2022-502424-43-00)
- 25 Jul 2023 Phase-I clinical trials in Unspecified (In volunteers) in Germany (PO) (NCT05945888)